{
  "drug_name": "Meropenem-vaborbactam",
  "tradename": "Vabomere",
  "usage_and_dosing": {
    "general": [
      "A combination of meropenem + vaborbactam, a cyclic boronic acid pharmacophore ẞ-lactamase inhibitor of Ambler case A and C enzymes (but not class B [metalloenzymes] or class D enzymes).",
      "The combination is approved for the the treatment of complicated urinary tract infections in adults (age ≥18 years) caused by E. coli, K. pneumoniae, E. cloacae, and other susceptible aerobic gram-negative bacilli.",
      "NOTE: the combination does not increase the activity of meropenem against Acinetobacter baumannii, Pseudomonas aeruginosa, or Stenotrophomonas maltophilia.",
      "An alternative antibiotic for drug resistant genotypes.",
      "Vaborbactam protects meropenem from degradation by extended spectrum beta-lactamases and serine carbapenemases (except class D OXA-enzymes)",
      "Review: Antibiotics 2023;12:1612."
    ],
    "adult_dose": {
      "usual_dose": "4 gm (over 3 hr) IV q8h",
      "note": "Note that 4 gm = Meropenem 2 gm + Vaborbactam 2 gm",
      "compatibility": "Compatible only with normal saline. Dissolved drug is stable at room temperature for 4 hr, and at 2-6 °C for 22 hr."
    },
    "pediatric_dose": {
      "note": "Doses are expressed as the sum of meropenem + vaborbactam (1:1 ratio)",
      "amr_gram_negative_guidance": "J Pediatric Infect Dis Soc 2025;14:piaf004",
      "per_fda": {
        "safety_and_efficacy": "not established"
      },
      "per_amr_gram_negative_guidance": {
        "infants_children_adolescents": {
            "doses_infused_over_3_hr": "240 mg/kg/day (divided q8h)"
        },
        "cns_infection": "Not recommended for CNS infection"
      },
      "max_day": "12 gm"
    }
  },
  "renal_adjustment": {
    "half_life_normal": {
        "mer": 1.2,
        "vab": 1.7
    },
    "half_life_esrd": {
        "mer": 10,
        "vab": "ND"
    },
    "dose_renal_function_normal": "2 gm/2 gm IV q8h",
    "crcl_or_egfr": "eGFR ≥50: No dosage adjustment. eGFR 30-49: 1 gm/1 gm q8h. eGFR 15-29: 1 gm/1 gm q12h. eGFR <15: 0.5 gm/0.5 gm q12h",
    "hemodialysis": "0.5 gm/0.5 gm q12h (AD)",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "other_adjustment": [
    "Obesity: See Obesity Dosing Adjustments page."
  ],
  "adverse_effects": [
    "Contraindications: known hypersensitivity reaction to meropenem or vaborbactam (or other beta-lactams)",
    "Adverse effects:",
    "Hypersensitivity reactions",
    "Seizure potential",
    "C. difficile associated diarrhea (CDAD)",
    "Thrombocytopenia",
    "Neuromotor impairment",
    "Other: Phlebitis (infusion site reactions), diarrhea, headache",
    "Risk of breakthrough seizures due to ability to decrease concentrations of valproic acid."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No human data, toxic in animals",
    "lactation": "Probably safe with monitoring, but no data available",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "Mer 43.4, Vab 55.6 (4 gm IV q8h, SS)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "Mer 2, Vab 33",
    "volume_of_distribution_vd_l_vss": "Mer 20.2L, Vab 18.6 L (Vss)",
    "avg_serum_half_life_hr": "Mer 1.22, Vab 1.68",
    "elimination": "Renal",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "Mer 138, Vab 196 (SS, 0-8 hr)"
  },
  "enzyme_transporter_mediated_interactions": {
      "cyp450s_substrate": [],
      "transporters_substrate": "Meropenem: OAT1, OAT3",
      "ugts_substrate": [],
      "cyp450s_inhibited": [],
      "transporters_inhibited": [],
      "ugts_inhibited": [],
      "cyp450s_induced": [],
      "transporters_induced": [],
      "ugts_induced": [],
      "impact_on_serum_drug_concentrations": "None expected"
  },
  "major_drug_interactions": [
      {
          "drug": "Valproic acid",
          "effect": "↓ valproic acid",
          "management": "Avoid co-administration"
      },
      {
          "drug": "Probenecid",
          "effect": "↑ meropenem",
          "management": "Monitor"
      }
  ],
  "comments": [
      "FDA approval based on results of a double-blind double-dummy, multicenter trial that compared meropenem-vaborbactam to piperacillin-tazobactam in adults with complicated urinary tract infections.",
      "Clinical cure and microbiologic eradication were essentially equivalent.",
      "Further details in the package insert."
  ]
}
